Quality Control Metrics for Whole Blood Transcriptome Analysis in the Parkinson′s Progression Markers Initiative (PPMI)

The Michael J. Fox Foundation9s Parkinson9s Progression Markers Initiative (PPMI) is an observational study to comprehensively evaluate Parkinson9s disease (PD) patients using imaging, biologic sampling, clinical and behavioral assessments to identify biomarkers of PD progression. As part of this study, we obtained 4,756 whole blood samples from 1,570 subjects at baseline, 0.5, 1, 2, and 3 years from enrollment in the study. We isolated RNA and performed whole transcriptome sequencing in this longitudinal cohort. Here, we describe and quantify technical variability associated with this dataset through the use of pooled reference samples, including plate distribution, RNA quality, and outliers. This large, uniformly processed dataset is available to researchers at https://www.ppmi-info.org.